<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68817">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912040</url>
  </required_header>
  <id_info>
    <org_study_id>123Iodine MIBG</org_study_id>
    <nct_id>NCT01912040</nct_id>
  </id_info>
  <brief_title>Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use</brief_title>
  <official_title>A Prospective, Open Label, Single Arm Cohort Study to Assess the Frequency of Adverse Reactions of Locally Manufactured 123I-metaiodobenzylguanidine in Routine Clinical Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital District Health Authority, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital District Health Authority, Canada</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing 123 Iodine MIBG produced locally for safety while being used in clinical practice
      to help in patient management decisions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will be assessing for adverse reactions of patients injected with locally manufactured
      123 Iodine MIBG. With monitoring of blood pressure and heart rate following injection and
      any potential immediate side effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Safety profile of the 123Iodine MIBG</measure>
    <time_frame>BP and Heart rate for 24 hours  after injection.</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Adrenergic Pathology</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Administration of 123Iodine MIBG to the patients referred .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of  123Iodine MIBG</intervention_name>
    <description>Patients will be administered the locally produced 123 Iodine MIBG</description>
    <arm_group_label>Patients</arm_group_label>
    <other_name>None applicable</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Those patients referred for MIBG assessment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with potential Adrenergic pathology

        Exclusion Criteria:

          -  Pregnant or breast feeding females

          -  Hypersensitivity to MIBG
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Ross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division Head, Nuclear Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Ross, MD</last_name>
    <phone>902-473-7770</phone>
    <email>aross@dal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christina Kelly, B.T.</last_name>
    <phone>902-473-4377</phone>
    <email>chrisitna.kelly@cdha.nshealth.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Capital District Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H2Y5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 29, 2013</lastchanged_date>
  <firstreceived_date>July 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital District Health Authority, Canada</investigator_affiliation>
    <investigator_full_name>Andrew Ross</investigator_full_name>
    <investigator_title>Division Head, Nuclear Medicine</investigator_title>
  </responsible_party>
  <keyword>Safety profile</keyword>
  <keyword>locally produced 123 Iodine MIBG</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
